VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Author:  Comi, G.
Author:  Sharrack, B.

Results 1-6 of 6 (Search time: 0.002 seconds).

Issue DateTitleContributor(s)TypeCat.
12019Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 yearsVermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, BartJournal ContributionM
22018Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extensionVAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H.Journal ContributionM
32018Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extensionWiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, BartJournal ContributionM
42018No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
52018No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
62017Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analysesComi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S.Journal ContributionM